Rezūm improved symptoms and quality of life at 1 year vs combination pharmacotherapy in sexually active men with BPO while preserving sexual function.
Related to this article
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Advertisement
Advertisement
Trending on Urology Times
1
Evaluating AI Tools for Prostate Cancer: What Urologists Should Ask
2
Benchmarking AI Risk Estimates in Prostate Cancer Against STAR-CAP
3
How should urologists coordinate IVF bladder symptom care?
4
Broader Adoption and Future Research in Rectal Spacing
5